GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Long-Term Debt

KYTX (Kyverna Therapeutics) Long-Term Debt : $0.00 Mil (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Long-Term Debt?

Kyverna Therapeutics's Long-Term Debt for the quarter that ended in Jun. 2024 was $0.00 Mil.


Kyverna Therapeutics Long-Term Debt Historical Data

The historical data trend for Kyverna Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Long-Term Debt Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Long-Term Debt
- - -

Kyverna Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Long-Term Debt Get a 7-Day Free Trial Premium Member Only - - - - -

Kyverna Therapeutics  (NAS:KYTX) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.


Kyverna Therapeutics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyverna Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
5980 Horton Street, STE 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics Headlines